Celldex Therapeutics (CLDX) News Today $24.45 -0.75 (-2.98%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$24.44 -0.01 (-0.04%) As of 09/12/2025 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Woodline Partners LP Sells 825,586 Shares of Celldex Therapeutics, Inc. $CLDXSeptember 13 at 4:36 AM | marketbeat.comCelldex Therapeutics (CLDX) Reports Promising Phase 2 Study Results For BarzolvolimabSeptember 10, 2025 | finance.yahoo.comCelldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comCelldex to Present at Morgan Stanley 23rd Annual Global Healthcare ConferenceSeptember 9, 2025 | globenewswire.comPolar Asset Management Partners Inc. Has $497,000 Stake in Celldex Therapeutics, Inc. $CLDXSeptember 9, 2025 | marketbeat.comCinctive Capital Management LP Sells 37,925 Shares of Celldex Therapeutics, Inc. $CLDXSeptember 8, 2025 | marketbeat.comTrexquant Investment LP Takes $1.42 Million Position in Celldex Therapeutics, Inc. $CLDXSeptember 8, 2025 | marketbeat.comNorthern Trust Corp Sells 20,244 Shares of Celldex Therapeutics, Inc. $CLDXSeptember 8, 2025 | marketbeat.comCelldex Therapeutics Advances in Prurigo Nodularis Treatment with Barzolvolimab StudySeptember 8, 2025 | msn.comPDT Partners LLC Makes New Investment in Celldex Therapeutics, Inc. $CLDXSeptember 7, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Trading 6.2% Higher - Here's WhySeptember 5, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 5, 2025 | marketbeat.com14,600 Shares in Celldex Therapeutics, Inc. $CLDX Bought by ADAR1 Capital Management LLCSeptember 4, 2025 | marketbeat.comRedmile Group LLC Cuts Stock Position in Celldex Therapeutics, Inc. $CLDXSeptember 4, 2025 | marketbeat.comVestal Point Capital LP Decreases Stock Position in Celldex Therapeutics, Inc. $CLDXSeptember 4, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 4, 2025 | americanbankingnews.comRafferty Asset Management LLC Has $1.97 Million Position in Celldex Therapeutics, Inc. $CLDXSeptember 2, 2025 | marketbeat.comCapital Fund Management S.A. Has $281,000 Position in Celldex Therapeutics, Inc. $CLDXAugust 30, 2025 | marketbeat.comCelldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic UrticariaAugust 29, 2025 | tipranks.comPrice T Rowe Associates Inc. MD Trims Stock Position in Celldex Therapeutics, Inc. $CLDXAugust 29, 2025 | marketbeat.comAmerican Century Companies Inc. Raises Stock Position in Celldex Therapeutics, Inc. $CLDXAugust 28, 2025 | marketbeat.comCelldex Therapeutics Advances Phase 3 Trial for Chronic Spontaneous Urticaria TreatmentAugust 27, 2025 | tipranks.comNuveen LLC Acquires Shares of 429,126 Celldex Therapeutics, Inc. $CLDXAugust 27, 2025 | marketbeat.comVanguard Group Inc. Has $70.76 Million Stake in Celldex Therapeutics, Inc. $CLDXAugust 26, 2025 | marketbeat.comWellington Management Group LLP Has $151.63 Million Stock Position in Celldex Therapeutics, Inc. $CLDXAugust 23, 2025 | marketbeat.comCelldex Therapeutics, Inc. $CLDX Position Boosted by Algert Global LLCAugust 23, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Shares Gap Down After Analyst DowngradeAugust 22, 2025 | marketbeat.comCanaccord Genuity Group Issues Pessimistic Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock PriceAugust 22, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Given New $42.00 Price Target at HC WainwrightAugust 22, 2025 | marketbeat.comDeutsche Bank AG Raises Stock Holdings in Celldex Therapeutics, Inc. $CLDXAugust 22, 2025 | marketbeat.comCelldex slides after Barzolvolimab hits target but fails to improve EoE symptoms in phase 2 trialAugust 20, 2025 | msn.comCelldex Therapeutics (NASDAQ:CLDX) Stock Price Down 4.7% - Here's WhyAugust 20, 2025 | marketbeat.comCelldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls ShortAugust 20, 2025 | benzinga.comLifeSci Capital Maintains a Buy on Celldex Therapeutics (CLDX), Keeps the PTAugust 20, 2025 | msn.comCelldex Halts Barzolvolimab Development for EoEAugust 19, 2025 | msn.comCelldex Therapeutics Inc (CLDX) Announces Phase 2 Study Results for Barzolvolimab in ...August 19, 2025 | gurufocus.comCelldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)August 19, 2025 | globenewswire.comWellington Management Group LLP Reduces Stake in Celldex Therapeutics IncAugust 17, 2025 | gurufocus.comCelldex Therapeutics Reports Increased R&D Expenses Amid Wider LossesAugust 15, 2025 | msn.comCelldex Therapeutics (NASDAQ:CLDX) Trading Up 7.2% - Should You Buy?August 13, 2025 | marketbeat.comCelldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Spontaneous UrticariaAugust 12, 2025 | tipranks.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by BrokeragesAugust 11, 2025 | marketbeat.comDecoding Celldex Therapeutics Inc (CLDX): A Strategic SWOT InsightAugust 7, 2025 | gurufocus.comCelldex Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 7, 2025 | globenewswire.comCelldex Therapeutics (CLDX) Projected to Post Quarterly Earnings on ThursdayAugust 7, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Buys Shares of 14,834 Celldex Therapeutics, Inc. (NASDAQ:CLDX)August 5, 2025 | marketbeat.comTD Asset Management Inc Sells 65,000 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)August 4, 2025 | marketbeat.comCelldex Therapeutics’ Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic UrticariaAugust 1, 2025 | tipranks.comGSA Capital Partners LLP Makes New Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)July 31, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 16, 2025 | marketbeat.com Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLDX Media Mentions By Week CLDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDX News Sentiment▼1.260.93▲Average Medical News Sentiment CLDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDX Articles This Week▼105▲CLDX Articles Average Week Get the Latest News and Ratings for CLDX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Celldex Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Alkermes News Ligand Pharmaceuticals News Amicus Therapeutics News BioCryst Pharmaceuticals News MannKind News Innoviva News Novavax News Dynavax Technologies News OPKO Health News Geron News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLDX) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone thought he was insane…SpaceX just struck a $17 billion deal with EchoStar for radio frequencies, and tech analyst Jeff Brown says it...Brownstone Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDX Stock Alerts